Antibiotic-resistant bloodstream infections in hospitalized patients: Specific risk factors in a high-risk population?

Infection

Volumn 33, Issue 5-6, 2005, Pages 320-326

  Von Baum, H ^a   Ober, J F ^b   Wendt, C ^c   Wenzel, R P ^b   Edmond, M B ^b  

^a UNIVERSITY OF ULM   (Germany)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CEFTAZIDIME; CEPHALOSPORIN; METICILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIAL VIRULENCE; BACTERIUM ISOLATION; BRONCHOSCOPY; BURN; CANDIDA; CONTROLLED STUDY; DIALYSIS; ENDOSCOPY; ENTEROBACTERIACEAE; FEMALE; HEALTH SURVEY; HIGH RISK PATIENT; HIGH RISK POPULATION; HOSPITAL INFECTION; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; RISK ASSESSMENT; STATISTICAL ANALYSIS; TRACHEOSTOMY; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ADULT; AGED; BACTEREMIA; CANDIDA; CANDIDIASIS; CEPHALOSPORIN RESISTANCE; CROSS INFECTION; DRUG RESISTANCE; ENTEROBACTERIACEAE; ENTEROCOCCUS; FEMALE; FUNGEMIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; METHICILLIN RESISTANCE; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANCE;

EID: 27644569627     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-005-5066-4     Document Type: Article

References (28)

1. Karchmer AW: Nosocomial bloodstream infections: organisms, risk factors, and im plications. Clin Infect Dis 2000; 31 (Suppl. 4): S139-S143.
2. Pittet D, Davis CS, Li N, Wenzel RP: Identifying the hospitalized patient at risk for nosocomial bloodstream infection: a population-based study. Proc Assoc Am Physicians 1997; 109: 58-67.
3. Schiappa DA, Hayden MK, Matushek MG: Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infections case-control and molecular epidemiologic investigation. J Infect Dis 1996; 174: 529-536.
4. Lautenbach E, Bilker WB, Brennan PJ: Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999; 20: 318-323.
5. Soriano A, Martinez JA, Mensa J, Marco F, Almela M, Moreno-Martinez A, Sanchez F, Munoz I, Jimenez de Anta MT, Soriano E: Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis 2000; 30: 368-373.
6. Pujol M, Pena C, Pallares R, Ayats J, Ariza J, Gudiol F: Risk factors for nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 1994; 13: 96-102.
7. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, Rangel-Frausto MS, Rinaldi MG, Saiman L, Wiblin RT, Wenzel RP; National Epidemiology of Mycoses Survey (NEMIS) Study Group. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clin Infect Dis 2001; 33: 177-186.
8. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP: Nosocomial bloodstream infections in United States hospitals: a 3-year analysis. Clin Infect Dis 1999; 29: 239-244.
9. Laupland KB, Davies HD, Church DL, Louie TJ, Dool JS, Zygun DA, Doing CJ: Bloodstream infection-associated sepsis and septic shock in critically ill adults: a population-based study. Infection 2004; 32: 59-64.
10. Edmond MB, Ober JF, Weinbaum DL: Vancomycin-resistant Enterococcus faecalis bacteremia: risk factors for infection. Clin Infect Dis 1995; 20: 1126-1133.
11. Baran J, Riederer KM, Ramanathan J, Khatib R: Recurrent vancomycin-resistant Enterococcus bacteremia: prevalence, predisposing factors, and strain relatedness. Clin Infect Dis 2001; 32: 1381-1383.
12. Vergis EN, Hayden MK, Chow JW, Snydman DR, Zervos MJ, Linden PK, Wagener MM, Schmitt B, Muder RR: Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. Ann Intern Med 2001; 135: 484-492.
13. Lynch JP: Hospital-acquired pneumonia. Risk factors, microbiology, and treatment. Chest 2001; 119 (Suppl. 2): 373S-384S.
14. Calil R, Marba STM, von Nowakonski A, Tresoldi AT: Reduction in colonization and nosocomial infection by multiresistant bacteria in a neonatal unit after institution of educational measures and restriction in the use of cephalosporins. Am J Infect Control 2001; 29: 133-138.
15. Menashe G, Borer A, Yagupsky P, Peled N, Gilad J, Fraser D, Riesenberg K, Schlaeffer F: Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia. Scand J Inf Dis 2001; 33: 188-193.
16. Bross J, Talbot GH, Maislin G, Hurwitz S, Strom BL: Risk factors for nosocomial candidemia: a case control study in adults without leukemia. Am J Med 1989; 87: 614-617.
17. Lunel FMV, Meis FGM, Voss A: Nosocomial fungal infections: Candidemia. Diagn Microbiol Infect Dis 1999; 34: 213-220.
18. Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA, Houston A, Coffman S, Hollis RJ: Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 2000; 44: 747-751.
19. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP: Risk factors for hospital-acquired candidemia : a matched case-control study. Arch Intern Med 1989; 149: 2349-2353.
20. Almirante B, Rodriguez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela M, Mensa J, Sanchez F, Ayats J, Gimenez M, Saballs P, Fridkin SK, Morgan J, Rodriguez-Tudela JL, Warnock DW, Pahissa A; Barcelona Candidemia Project Study Group: Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain,from 2002 to 2003. J Clin Microbiol 2005; 43: 1829-1835.
21. Asensio A, Guerrero A, Quereda C, Lizan M, Martinez-Ferrer M: Colonization and infection with methicillin-resistant Staphylococcus aureus: associated factors and eradication. Infect Control Hosp Epidemiol 1996 ; 17: 20-28.
22. Crowcroft N, Maguire H, Fleming M, Peacock J, Thomas J: Methicillin-resistant Staphylococcus aureus: investigation of a hospital outbreak using a case-control study. J Hosp Infect 1996; 34: 301-309.
23. Monnet DL: Methicillin-resistant Staphylococcus aureus and its relationship to antimicrobial use: possible implications for control. Infect Control Hosp Epidemiol 1998; 19: 552-559.
24. Hill DA, Herford T, Parratt D: Antibiotic usage and methicillin-resistant Staphylococcus aureus: an analysis of causality. J Antimicrob Chemother 1998; 42: 676-677.
25. DÁgata EMC, Green WK, Schulman C, Li H, Tang YW, Schaffner W: Vancomycin-resistant enterococci among chronic hemodialysis patients: a prospective study of acquisition. Clin Infect Dis 2001; 32: 23-29.
26. Fridkin SK, Edwards JR, Courval JM, Hill H, Tenover FC, Lawton R, Gaynes RP, McGowan JE Jr; Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project and the National Nosocomial Infections Surveillance (NNIS) System Hospitals: The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann Intern Med 2001; 135: 175-183.
27. Rex JH, Sobel JD: Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001; 32: 1191-1200.
28. Anatoliotaki M, Valatas V, Mantadakis E, Apostolakou H, Mavroudis D, Georgoulias V, Rolston KV, Kontoyiannis DP, Galanakis E, Samonis C: Bloodstream infections in patients with solid tumors: associated factors, microbial spectrum and outcome. Infection 2004; 32: 65-71.